Literature DB >> 25078484

Transfection of hBMP-2 into mesenchymal stem cells derived from human umbilical cord blood and bone marrow induces cell differentiation into chondrocytes.

J Wang1, J Li, N Deng, X Zhao, Y Liu, X Wang, H Zhang.   

Abstract

AIM: Objective of the study was to compare the liposome-mediated transfection efficiency of the recombinant plasmid pIRES2-EGFP-hBMP-2 into mesenchymal stem cells (MSCs) derived from human umbilical cord blood (UCB-MSCs) and bone marrow (BM-MSCs).
METHODS: UCB-MSCs and BM-MSCs were isolated using density gradient centrifugation followed by adherent cultures. The plasmid (pIRES2-EGFP-hBMP-2) was transfected into MSCs by using X-treme GENE transfection kit. Successful transfection was determined by both the protein expression of EGFP observed by fluorescence microscopy and the mRNA expression of human bone morphogenetic protein-2 (hBMP-2) detected using RT-PCR. Cell surface marker and morphological changes were examined by immunohistochemistry (IHC) after two weeks of transfection.
RESULTS: Both UCB-MSCs and BM-MSCs were isolated and expanded successfully for multiple passages and demonstrated slight growth and morphological differences. The recombinant plasmid (pIRES2-EGFP-hBMP-2) was successfully transfected into both UCB-MSCs and BM-MSCs with an efficiency of 27.7 ± 7.6% and 18.4 ± 5.9%, respectively. The mRNA expression of hBMP-2 correlated with increased staining for collagen type II in the transfected cells.
CONCLUSION: Transfection of hBMP-2 in UCB-MSCs and BM-MSCs increases the expression of collagen type II. These results indicate that increased BMP-2 levels induce multipotent stem cell differentiation into chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25078484

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  5 in total

1.  Gene Therapy for Bone Repair Using Human Cells: Superior Osteogenic Potential of Bone Morphogenetic Protein 2-Transduced Mesenchymal Stem Cells Derived from Adipose Tissue Compared to Bone Marrow.

Authors:  Sofia Bougioukli; Osamu Sugiyama; William Pannell; Brandon Ortega; Matthew H Tan; Amy H Tang; Robert Yoho; Daniel A Oakes; Jay R Lieberman
Journal:  Hum Gene Ther       Date:  2018-03-14       Impact factor: 5.695

2.  Improved osteogenesis and upregulated immunogenicity in human placenta-derived mesenchymal stem cells primed with osteogenic induction medium.

Authors:  Xuejie Fu; Huilin Yang; Hui Zhang; Guichao Wang; Ke Liu; Qiaoli Gu; Yunxia Tao; Guangcun Chen; Xiaohua Jiang; Gang Li; Yanzheng Gu; Qin Shi
Journal:  Stem Cell Res Ther       Date:  2016-09-20       Impact factor: 6.832

3.  The human umbilical cord stem cells improve the viability of OA degenerated chondrocytes.

Authors:  Hao Wang; Xu Yan; Yuxin Jiang; Zheng Wang; Yufei Li; Qingdong Shao
Journal:  Mol Med Rep       Date:  2018-01-09       Impact factor: 2.952

Review 4.  Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells.

Authors:  Soyoun Um; Jueun Ha; Soo Jin Choi; Wonil Oh; Hye Jin Jin
Journal:  World J Stem Cells       Date:  2020-12-26       Impact factor: 5.326

5.  Hypoxia Is a Critical Parameter for Chondrogenic Differentiation of Human Umbilical Cord Blood Mesenchymal Stem Cells in Type I/III Collagen Sponges.

Authors:  Tangni Gómez-Leduc; Mélanie Desancé; Magalie Hervieu; Florence Legendre; David Ollitrault; Claire de Vienne; Michel Herlicoviez; Philippe Galéra; Magali Demoor
Journal:  Int J Mol Sci       Date:  2017-09-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.